Ms. Kristina Hachey reports

THERALASE(R) CLOSES $1.3 M NON-BROKERED PRIVATE PLACEMENT

Theralase Technologies Inc. has successfully closed a non-brokered private placement offering of units.

On closing, the corporation issued an aggregate of 7,850,882 units at a price of 17 cents per unit for aggregate gross proceeds of approximately $1,334,650.

Each unit consists of one common share of the company and one common share purchase warrant. Each warrant entitles the holder to acquire an additional common share at an exercise price of 21 cents per share for a period of five years following the date of closing.

The company plans to use the proceeds of the financing to further the phase II non-muscle invasive bladder cancer (NMIBC) clinical study currently under way, working capital and general corporate purposes.

In connection with the offering, the company paid a finder's fee of $31,658, of which $15,470 was paid in cash and $16,188 was paid through the issuance of 95,221 common shares. In addition, the company issued 186,221 non-transferable finder warrants. Each finder warrant is exercisable into one common share at an exercise price of 21 cents per share for a period of five years following the date of closing.

All securities issued under the offering will be subject to a four-month-and-one-day hold period from the closing date under applicable Canadian securities laws, which expires on April 24, 2026.

The offering is subject to receipt of final acceptance from the TSX Venture Exchange.

About Theralase Technologies Inc.

Theralase is a clinical-stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue.

We seek Safe Harbor.